Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2026-06-22

Clinical Trial Update: A Study to Test the Long-term Treatment of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa [Phase 3]

View source ↗

Summary

Phase 3 clinical trial update for long-term use of bimekizumab in moderate to severe hidradenitis suppurativa.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Bimekizumab (bimekizumab)

Snippet

Sponsor: UCB Biopharma SRL | Conditions: Hidradenitis Suppurativa | Phase 3 | Status: ACTIVE_NOT_RECRUITING